European Investment Fund

WEMIX expands global reach with its first Europe listing on Bit2Me, Spain’s largest virtual asset exchange

Retrieved on: 
Wednesday, February 7, 2024

WEMIX functions as a resource with economic value that is used for everything from yield farming, staking and swaps, to governance.

Key Points: 
  • WEMIX functions as a resource with economic value that is used for everything from yield farming, staking and swaps, to governance.
  • It is also used as a medium for exchange, payments and transactions including in-game purchases.
  • The Bit2Me listing is a significant milestone for being the very first WEMIX listing on a cryptocurrency exchange based in Europe.
  • It also marks the start of plans by the WEMIX Foundation to increase accessibility and convenience to WEMIX for over 450 million Spanish speakers worldwide.

Seroba Announces Above Target Final Close of its Fund IV at €123M ($134M)

Retrieved on: 
Thursday, February 1, 2024

Seroba, a European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, announced today the final close of its Seroba Fund IV at €123M ($134M).

Key Points: 
  • Seroba, a European life sciences venture capital firm headquartered in Dublin, with offices in Paris and Milan, announced today the final close of its Seroba Fund IV at €123M ($134M).
  • The Fund will target up to 12 investments and has, to date, invested in 5 companies: Perfuze, Sibylla Biotech, Deciphex, Complement Therapeutics and Artica Therapeutics.
  • Fund IV will focus on innovative early-stage investments in life sciences companies, predominantly in Western Europe, and selectively in North America, with a primary focus on biotech.
  • With a pan-European footprint, the Seroba team continues to assess a rich pipeline of investment opportunities in its focus areas.

Audacia SAS: Expansion Ventures to begin operation with a €100 million 1st closing, anchored by a €60 million investment from EIF

Retrieved on: 
Tuesday, January 30, 2024

Audacia SAS: Expansion Ventures to begin operation with a €100 million 1st closing, anchored by a €60 million investment from EIF

Key Points: 
  • Audacia SAS: Expansion Ventures to begin operation with a €100 million 1st closing, anchored by a €60 million investment from EIF
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • EIF commitment represents a significant milestone for Expansion and reaffirms its role as a supporter of European New Space and New Air Mobility industries.
  • Expansion, with the support of EIF, aims at reducing that gap, by providing financing and expertise to the best European entrepreneurs in this sector.
  • For more information about Expansion and its initiatives in the New Space and New Space Mobility sectors, please visit https://www.expansion-vc.eu/

Fasanara acquires specialist gaming/app lender Pollen VC

Retrieved on: 
Wednesday, January 24, 2024

LONDON, Jan. 24, 2024 /PRNewswire-PRWeb/ -- Fasanara, a London-headquartered specialist credit asset manager and technology platform with over $4 billion in total assets, acquires a majority stake in Pollen VC, a leading provider of non-dilutive working capital to the mobile gaming/app sector.

Key Points: 
  • LONDON, Jan. 24, 2024 /PRNewswire-PRWeb/ -- Fasanara , a London-headquartered specialist credit asset manager and technology platform with over $4 billion in total assets, acquires a majority stake in Pollen VC , a leading provider of non-dilutive working capital to the mobile gaming/app sector.
  • "We are delighted to welcome Pollen VC into the Fasanara family.
  • Pollen VC provides revolving credit facilities to mobile app and game developers based on their receivables to help them scale, without relying on dilutive VC capital to fund their marketing spend.
  • Francesco Filia, Founder & CEO of Fasanara said, "We are delighted to welcome Pollen VC into the Fasanara family.

Mironid extends Series A round raising £35 million to date for development of first-in-class small molecules to treat life-threatening hereditary kidney disease

Retrieved on: 
Wednesday, September 13, 2023

The Company will use the proceeds to progress its lead discovery programme through IND-enabling studies and to extend its patent estate.

Key Points: 
  • The Company will use the proceeds to progress its lead discovery programme through IND-enabling studies and to extend its patent estate.
  • It affects over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60.
  • The disease is caused predominantly by mutations in the PKD1 or PKD2 gene and is characterized by uncontrolled growth of fluid-filled cysts in the kidney.
  • Robust in vitro and disease model data show significant efficacy across all disease endpoints, including a reduction in cyst number and kidney volume.

Infinity Recycling's Circular Plastics Fund Reaches €105 Million Committed Capital

Retrieved on: 
Wednesday, September 6, 2023

ROTTERDAM, The Netherlands, Sept. 6, 2023 /PRNewswire/ -- Infinity Recycling BV, a growth capital firm investing in advanced plastics recycling technologies, is pleased to announce the highly anticipated new closing of its Circular Plastics Fund I (CPF), achieving €105.3 million in committed capital.

Key Points: 
  • ROTTERDAM, The Netherlands, Sept. 6, 2023 /PRNewswire/ -- Infinity Recycling BV, a growth capital firm investing in advanced plastics recycling technologies, is pleased to announce the highly anticipated new closing of its Circular Plastics Fund I (CPF), achieving €105.3 million in committed capital.
  • The CPF, with an initial target size of €150 million, is an Article 9 'dark green' impact fund under the EU's Sustainable Finance Disclosure Regulation.
  • Their first offering, the Circular Plastics Fund, contributes to solving the plastic waste problem and unlocking much-needed capacity in high-in-demand recycled commodities.
  • The fund implements a return and impact-driven investment strategy that drives value creation in advanced recycling and accelerates the transition to a circular economy for plastics.

Infinity Recycling's Circular Plastics Fund Reaches €105 Million Committed Capital

Retrieved on: 
Wednesday, September 6, 2023

ROTTERDAM, The Netherlands, Sept. 6, 2023 /PRNewswire/ -- Infinity Recycling BV, a growth capital firm investing in advanced plastics recycling technologies, is pleased to announce the highly anticipated new closing of its Circular Plastics Fund I (CPF), achieving €105.3 million in committed capital.

Key Points: 
  • ROTTERDAM, The Netherlands, Sept. 6, 2023 /PRNewswire/ -- Infinity Recycling BV, a growth capital firm investing in advanced plastics recycling technologies, is pleased to announce the highly anticipated new closing of its Circular Plastics Fund I (CPF), achieving €105.3 million in committed capital.
  • The CPF, with an initial target size of €150 million, is an Article 9 'dark green' impact fund under the EU's Sustainable Finance Disclosure Regulation.
  • Their first offering, the Circular Plastics Fund, contributes to solving the plastic waste problem and unlocking much-needed capacity in high-in-demand recycled commodities.
  • The fund implements a return and impact-driven investment strategy that drives value creation in advanced recycling and accelerates the transition to a circular economy for plastics.

Vesalius Biocapital Announces First Close of Fourth Fund Raising EUR 95 Million

Retrieved on: 
Thursday, June 29, 2023

STRASSEN, Luxembourg, June 29, 2023 /PRNewswire/ -- Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.

Key Points: 
  • STRASSEN, Luxembourg, June 29, 2023 /PRNewswire/ -- Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.
  • Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life science companies in drug development and digital health.
  • Commenting on the first close, Stéphane Verdood, Managing Partner at Vesalius Biocapital IV said:
    "Our successful track record placed us in a strong position to attract high quality investors such as the EIF (European Investment Fund) to Vesalius Biocapital IV.
  • Vesalius Biocapital IV is targeting €150M and will accept new investors on a "rolling closing" basis until the final closing in 2024.

Vesalius Biocapital Announces First Close of Fourth Fund Raising EUR 95 Million

Retrieved on: 
Thursday, June 29, 2023

STRASSEN, Luxembourg, June 29, 2023 /PRNewswire/ -- Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.

Key Points: 
  • STRASSEN, Luxembourg, June 29, 2023 /PRNewswire/ -- Vesalius Biocapital, the specialist life sciences venture capital investor, announces the first close of its fourth fund, Vesalius Biocapital IV, securing over €95 million of commitments.
  • Starting immediately Vesalius Biocapital IV is to invest in first and best-in-class European life science companies in drug development and digital health.
  • Commenting on the first close, Stéphane Verdood, Managing Partner at Vesalius Biocapital IV said:
    "Our successful track record placed us in a strong position to attract high quality investors such as the EIF (European Investment Fund) to Vesalius Biocapital IV.
  • Vesalius Biocapital IV is targeting €150M and will accept new investors on a "rolling closing" basis until the final closing in 2024.

Space company Isar Aerospace secures Series C Funding Round of USD 165m to meet global demand for access to space

Retrieved on: 
Tuesday, March 28, 2023

The funding enables Isar Aerospace to continue its journey towards the inaugural flight and ramp-up the cadence of its Spectrum launch vehicle.

Key Points: 
  • The funding enables Isar Aerospace to continue its journey towards the inaugural flight and ramp-up the cadence of its Spectrum launch vehicle.
  • Isar Aerospace offers the access to space that is urgently needed for commercial, institutional and government customers.
  • With a total financing amount raised of more than USD 330m (EUR 310m), Isar Aerospace is the most capitalized independent New Space company in the European Union.
  • Isar Aerospace has signed firm contracts with customers globally, including major commercial players, New Space companies, and government institutions.